LAUSR

Background: Testosterone is inversely correlated with weight and waist circumference (WC). Methods: Of 324 men with hypogonadism and T2DM in a registry, 257 (79.3%) were obese, 60 (18.5%) overweight and 7 (2.2%) had normal weight. 152 received TU 1000 mg/12 weeks (T-group), 172 opted against treatment (CTRL). Changes over time between groups were compared by mixed effects model for repeated measures with random effect for intercept and fixed effects for time, group and their interaction, and adjusted for age, weight, WC, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the two groups. Results: Mean age: 62.7±5.1, follow-up: mean: 7.9, median: 9 years. T-group: weight decreased by 21.4±0.5 kg at 10 years. CTRL: weight increased by 4.8±0.4 kg. Estimated adjusted difference between groups: 26.2 kg (p Conclusions: Long-term testosterone therapy with TU in men with hypogonadism and T2DM sustainably improved anthropometric measures which worsened in untreated controls. Disclosure A. Haider: Research Support; Self; Bayer AG. Speaker9s Bureau; Self; Bayer AG. K.S. Haider: Speaker9s Bureau; Self; Bayer AG. F. Saad: Employee; Self; Bayer AG. Stock/Shareholder; Self; AbbVie Inc., Amgen Inc., Bayer AG. Funding Bayer AG